Therefore, we are currently evaluating whether this 177Lu-PSMA-617-therapy, using the same therapy regimen and activity which has already shown to be associated with limited adverse effects in prostate cancer, will be as effective in patients suffering from irresectable recurrent and/or metastatic AdCC. Here, FOLH1 is linked to prostate carcinoma.